Researchers at The University of Texas MD Anderson Cancer Center have discovered that an investigational epigenetic therapy ...
Preclinical study results suggest that targeting Hippo signaling may help address treatment resistance in acute myeloid ...
With the publication of the long-term data from the RELAZA2 study, a research program developed over many years by Dresden University Medicine for the treatment of leukemia patients, has reached an ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The risk of relapse for AML depends on the ...
Several patients with acute myeloid leukemia (AML) who were treated with SENTI-202, a chimeric antigen receptor natural killer (CAR-NK) therapy, experienced complete remission after not responding to ...
New research from the real-world setting supports key thresholds of measurable residual disease (MRD) negativity in NPM1-mutated acute myeloid leukemia (AML) that can predict disease relapse. The ...
A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. The updated ...
Both Annamycin dose arms outperformed control on the primary endpoint of complete remission (CR): 43% and 36% versus 12% — reported on a full ...
A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. Led by Mikkael ...
This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz. I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results